The FDA expanded the indication for mycophenolate mofetil (CellCept, Genentech) to allow it to be used as prophylaxis against organ rejection in children as young as 3 months of age, who require allogeneic heart and allogeneic liver transplantation.
Mycophenolate mofetil should be prescribed in combination with other immunosuppressants. The medication is available in tablet, capsule, IV and oral formulations.